Literature DB >> 7271272

Pharmacokinetics of netilmicin in children with and without cystic fibrosis.

H Michalsen, T Bergan.   

Abstract

The pharmacokinetics of intravenous netilmicin was studied in cystic fibrosis (CF) and non-CF patients who were closely matched according to age. The serum concentrations showed a moderately higher variance within the CF group. The serum half-life in CF patients was 1.37 h compared with 2.29 h in the non-CF subjects (P less than 0.05). The apparent distribution coefficients were 0.306 and 0.356 liters/kg in the CF and non-CF groups, respectively. The mean body clearance was 6.6 liters/h per 1.73 m2 in the CF group compared with 5.3 liters/h per m2 in the non-CF controls, but the difference was not significant. The mean renal clearance in CF patients was 4.7 liters/h per 1.73 m2. From a pharmacokinetic point of view, the dosage of netilmicin required may be the same in CF as in non-CF patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7271272      PMCID: PMC181602          DOI: 10.1128/AAC.19.6.1029

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Renal pharmacology of netilmicin.

Authors:  P J Chiu; G H Miller; A D Brown; J F Long; J A Waitz
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

2.  Pharmacokinetic study of netilmicin.

Authors:  B R Meyers; S Z Hirschman; G Wormser; D Siegel
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

3.  Bioavailability of oral antibiotics in cystic fibrosis.

Authors:  J P Guggenbichler; G Kienel
Journal:  Monogr Paediatr       Date:  1979

4.  Aminoglycoside clearance in patients with cystic fibrosis.

Authors:  E Finkelstein; K Hall
Journal:  J Pediatr       Date:  1979-01       Impact factor: 4.406

5.  Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis.

Authors:  W J Jusko; L L Mosovich; L M Gerbracht; M E Mattar; S J Yaffe
Journal:  Pediatrics       Date:  1975-12       Impact factor: 7.124

6.  Pharmacokinetics of azlocillin in children with cystic fibrosis.

Authors:  T Bergan; H Michalsen
Journal:  Arzneimittelforschung       Date:  1979

7.  Kinetics of netilmicin in man.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

8.  Pharmacokinetics of methicillin in patients with cystic fibrosis.

Authors:  S J Yaffe; L M Gerbracht; L L Mosovich; M E Mattar; M Danish; W J Jusko
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

9.  Multicompartment pharmacokinetics of netilmicin.

Authors:  M Wenk; P Spring; S Vozeh; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

  9 in total
  10 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 3.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 4.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients.

Authors:  J A Bosso; P L Townsend; J J Herbst; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 6.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Azlocillin pharmacokinetics in patients with cystic fibrosis.

Authors:  J A Bosso; B A Saxon; J J Herbst; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.

Authors:  B A Christensson; I Nilsson-Ehle; B Ljungberg; A Lindblad; A S Malmborg; L Hjelte; B Strandvik
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.